Drug Profile
Research programme: immunological disorders - Nodality/UCB
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Nodality; UCB
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Immunological-disorders in Belgium
- 04 Nov 2017 No recent reports of development identified for research development in Immunological-disorders in USA
- 17 Apr 2013 Early research is ongoing in USA and Belgium